MedTrace Logo

Effects of HMB and Rehabilitation Program in Athletes With Patellar Tendinopathy

NCT07466407 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-12

No results posted yet for this study

Summary

This randomized, double-blind, placebo-controlled clinical trial evaluates the effects of oral beta-hydroxy-beta-methylbutyrate (HMB) supplementation combined with an eccentric exercise and extracorporeal shockwave rehabilitation program on pain, tendon morphology, and neuromuscular performance in athletes with patellar tendinopathy.

Thirty athletes with a confirmed diagnosis of patellar tendinopathy are randomized to receive either HMB supplementation (3 g/day) or placebo during an 8-week rehabilitation program. Participants are evaluated at baseline, week 4, and week 8.

The primary outcome is pain and functional limitation assessed using the Victorian Institute of Sport Assessment-Patella (VISA-P) questionnaire. Secondary outcomes include patellar tendon thickness measured by ultrasound imaging, countermovement jump (CMJ) performance, and neuromuscular performance variables derived from an incremental squat test using a linear position transducer.

The aim of the study is to determine whether HMB supplementation enhances clinical recovery and neuromuscular performance when combined with a standardized rehabilitation program compared with placebo.

Conditions

  • Patellar Tendinopathy

Interventions

OTHER

Eccentric exercise and extracorporeal shock wave therapy

Participants undergo a standardized rehabilitation program consisting of eccentric exercise and extracorporeal shock wave therapy.

DIETARY_SUPPLEMENT

Beta-hydroxy-beta-methylbutyrate (HMB)

Participants ingest 3 g/day of beta-hydroxy-beta-methylbutyrate (HMB) in capsule form, administered 60 minutes before each eccentric training session during the 8-week intervention period.

Sponsors & Collaborators

  • Universidad de Córdoba

    collaborator OTHER

  • University of Seville

    collaborator OTHER

  • Universidad Complutense de Madrid

    lead OTHER

Principal Investigators

  • Juan J Ramos-Álvarez, MD · Universidad Complutense de Madrid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-06-01
Completion
2026-07-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07466407 on ClinicalTrials.gov